explore -WSS

explore

author：hotspot 2025-08-10 11:42:45 - browse：786

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Wegovy’s successful heart trial raises vital question about weight loss

WSS

Biotech lab space demand falls sharply

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Drug for rare kidney disease narrowly misses mark in clinical trial

Drastic changes should bring profitability, startup health insurers say

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Biotech lab space demand falls sharply

Wikipedia

explore

knowledge

Guidelines to prevent youth baseball injuries need more muscle

American woman, child freed after being kidnapped in Haiti last month

Hepatitis C has a cure — but many Americans still lack access to it

CommonSpirit Health keeps growing, even as it loses money

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Microbiome research is starting to find links to chronic diseases

Walensky prepares to leave CDC — and Congress — behind

How to use technology to prevent future drug shortages

Hollywood unions extend contract negotiations for actors

FDA panel issues narrow recommendation for Covid vaccine booster doses

entertainment

Man killed during FBI raid in connection with threats against Biden, other officials

Why failed clinical trials don’t always spell doom for a new drug

CDC's new outbreak response network to include Northeastern

Microbiome research is starting to find links to chronic diseases

How to use technology to prevent future drug shortages

Changes to biosimilar regulatory framework must prioritize patients

entertainment

explore

hotspot

leisure time